Tuesday, March 17, 2026

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

Elon Musk’s AI Grok Goes Off the Rails — And the Internet Noticed

Elon Musk's AI chatbot Grok faces backlash for controversial claims, highlighting concerns about AI reliability and manipulation.

NCCN Endorses Leclaza and Rybrevant Combo as Top Lung Cancer Treatment: What You Need to Know

NCCN guidelines now classify Leclaza + Rybrevant as a preferred first-line treatment for lung cancer, enhancing patient access and management.

Tag: military security

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

No posts to display

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.